SCHEMBL19580645

SCHEMBL19580645

CCn1nc2cc(Cl)ccc2c1-c1ccc[nH]1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KDM4C Q9H3R0 4/20 0.53
▸ HSF1 Q00613 2/20 0.36
▸ CYP1A2 P05177 2/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ ALDH1A1 P00352 2/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ CSF1R P07333 1/20 0.33
▸ MCL1 Q07820 1/20 0.33
▸ ADORA3 P0DMS8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19580763 0.82 KDM4C (0.50) KDM4CCYP1A2MAPTALDH1A1MEN1
SCHEMBL19580359 0.77 KDM4C (0.51) KDM4CHSF1MEN1KMT2A
SCHEMBL17686461 0.77 KDM4C (0.62) KDM4CALDH1A1MEN1KMT2AKDM4E
SCHEMBL19580369 0.72 KDM4C (0.49) KDM4CCYP1A2MAPTALDH1A1MEN1
SCHEMBL14738128 0.72 KDM4C (0.43) KDM4CCYP1A2CYP3A4MAPTCYP2C9
SCHEMBL21204939 0.71 KDM4C (0.72) KDM4CALDH1A1MEN1KMT2AKDM4E
SCHEMBL17610172 0.70 KDM4C (1.00) KDM4C
SCHEMBL17610212 0.68 KDM4C (0.81) KDM4CKMT2A
SCHEMBL19580720 0.67 KDM4C (0.48) KDM4CCYP1A2ALDH1A1MEN1KMT2A
SCHEMBL5076731 0.63 KDM4E (0.49) L3MBTL1MEN1KMT2AKDM4EMCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10231957-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2019-03-19 — — US disclosed
US-20180271843-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2018-09-27 — — US disclosed
US-10016401-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2018-07-10 — — US disclosed
US-20170326116-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RES INC (US) 2017-11-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10016401-B2 Histone demethylase inhibitors KDM1B, KDM1A, KDM5A KDM4C 12/4885HSF1 2685/4885CYP1A2 1918/4885
US-20180271843-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM1A, KDM5A KDM4C 12/4885HSF1 2685/4885CYP1A2 1918/4885
US-10231957-B2 Histone demethylase inhibitors KDM1B, KDM1A, KDM5A KDM4C 12/4885HSF1 2685/4885CYP1A2 1918/4885
US-20170326116-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM1A, KDM5A KDM4C 12/4885HSF1 2685/4885CYP1A2 1918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback